SAGE 217

Drug Profile

SAGE 217

Alternative Names: SAGE-217

Latest Information Update: 05 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SAGE Therapeutics
  • Class Antidepressants; Antiepileptic drugs; Antiparkinsonians; Sleep disorder therapies; Small molecules
  • Mechanism of Action GABA A receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Seizures

Highest Development Phases

  • Phase III Major depressive disorder; Postnatal depression
  • Phase II Bipolar depression; Essential tremor; Insomnia; Parkinson's disease
  • Phase I Seizures
  • Preclinical Dyskinesias

Most Recent Events

  • 14 Sep 2018 Sage Therapeutics plans a phase III trial for Major depressive disorder in September 2018 (PO) (NCT03672175)
  • 31 Aug 2018 Phase-III clinical trials in Major depressive disorder in USA (PO) (SAGE Therapeutics pipeline, September 2018)
  • 07 Aug 2018 Sage Therapeutics intends to seek feedback from US FDA regarding development in Sleep disorders in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top